Arcus Biosciences, Inc. to Post Q1 2025 Earnings of ($0.80) Per Share, Wedbush Forecasts (NYSE:RCUS)

Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) - Research analysts at Wedbush issued their Q1 2025 earnings estimates for shares of Arcus Biosciences in a research report issued on Wednesday, May 8th. Wedbush analyst R. Driscoll anticipates that the company will earn ($0.80) per share for the quarter. Wedbush has a "Outperform" rating and a $30.00 price objective on the stock. The consensus estimate for Arcus Biosciences' current full-year earnings is ($3.59) per share. Wedbush also issued estimates for Arcus Biosciences' Q2 2025 earnings at ($0.87) EPS, Q3 2025 earnings at ($0.89) EPS, Q4 2025 earnings at ($0.90) EPS and FY2028 earnings at $1.98 EPS.

A number of other equities analysts also recently weighed in on the stock. Mizuho lowered their target price on shares of Arcus Biosciences from $51.00 to $42.00 and set a "buy" rating for the company in a research note on Tuesday, January 30th. Truist Financial reissued a "buy" rating and set a $50.00 target price on shares of Arcus Biosciences in a research note on Monday, March 25th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, Arcus Biosciences presently has a consensus rating of "Moderate Buy" and an average target price of $41.25.

Arcus Biosciences Trading Up 3.4 %

Arcus Biosciences stock traded up $0.55 during mid-day trading on Friday, reaching $16.70. The company had a trading volume of 966,756 shares, compared to its average volume of 776,023. Arcus Biosciences has a fifty-two week low of $12.95 and a fifty-two week high of $25.47. The company has a market cap of $1.52 billion, a P/E ratio of -4.26 and a beta of 0.91. The business has a fifty day simple moving average of $16.95 and a 200 day simple moving average of $16.58.

Arcus Biosciences (NYSE:RCUS - Get Free Report) last announced its earnings results on Wednesday, May 8th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.97) by $0.92. The firm had revenue of $145.00 million for the quarter, compared to analyst estimates of $28.77 million. Arcus Biosciences had a negative net margin of 262.39% and a negative return on equity of 57.17%. The business's revenue was up 480.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($1.09) EPS.

Insider Activity

In other news, President Juan C. Jaen sold 3,900 shares of the firm's stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $20.06, for a total value of $78,234.00. Following the completion of the transaction, the president now directly owns 1,211,365 shares in the company, valued at $24,299,981.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other news, COO Jennifer Jarrett sold 11,551 shares of Arcus Biosciences stock in a transaction dated Wednesday, March 27th. The stock was sold at an average price of $17.55, for a total transaction of $202,720.05. Following the completion of the sale, the chief operating officer now owns 215,253 shares in the company, valued at approximately $3,777,690.15. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, President Juan C. Jaen sold 3,900 shares of the company's stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $20.06, for a total transaction of $78,234.00. Following the completion of the transaction, the president now owns 1,211,365 shares in the company, valued at $24,299,981.90. The disclosure for this sale can be found here. Over the last three months, insiders sold 53,455 shares of company stock worth $1,014,779. 12.30% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Arcus Biosciences

Hedge funds have recently added to or reduced their stakes in the company. Decheng Capital LLC bought a new stake in Arcus Biosciences in the fourth quarter valued at approximately $16,613,000. Barclays PLC boosted its holdings in shares of Arcus Biosciences by 183.4% during the 3rd quarter. Barclays PLC now owns 470,776 shares of the company's stock valued at $8,451,000 after buying an additional 304,683 shares in the last quarter. FMR LLC boosted its holdings in shares of Arcus Biosciences by 4.9% during the 3rd quarter. FMR LLC now owns 4,780,052 shares of the company's stock valued at $85,802,000 after buying an additional 222,280 shares in the last quarter. Vanguard Group Inc. boosted its stake in Arcus Biosciences by 4.2% in the 4th quarter. Vanguard Group Inc. now owns 4,680,716 shares of the company's stock worth $89,402,000 after purchasing an additional 186,898 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in Arcus Biosciences by 11.0% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,594,609 shares of the company's stock worth $30,459,000 after purchasing an additional 158,094 shares in the last quarter. Institutional investors own 92.89% of the company's stock.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.